Jason Peterson, R.Ph.

With over 15 years of pharmacy benefit management experience, Jason Peterson is a key member of the clinical team overseeing RemedyOne formulary management, clinical policy development, pipeline reporting and trend analysis of pharmacy benefits for our clients. Jason’s experience is leveraged to identify spend and trend analysis of both pharmacy and medical benefit cost of care and utilization to identify opportunities for enhanced clinical effectiveness and savings. In his previous role as a prior authorization pharmacist Jason provided complete oversight of a prior authorization processing operation at a long-term care pharmacy. He was responsible for providing clinical solutions for pharmacy claim resolution and engagement in cost efficient clinical programs. During this time, Jason developed particular expertise in pharmacy benefits management focused heavily on specialty and medical pharmacy where he provided oversight of clinical policy development, utilization management strategy, formulary management, pharmacy pipeline reporting, therapeutic class and new drug to market review and strategy, client implementation and support, and involvement with P&T and value assessment committees. Leveraging his extensive pharmaceutical experience, Jason also held a lead clinical pharmacist role at a health plan which included development and participation in member- and provider- facing clinical quality programs including STARS and HEDIS measures for all lines of business.

Weighing the Pros and Cons, and Dollars and Cents, of the New Wave of Weight-Loss Drugs

See this article by RemedyOne senior manager of formulary development Jason Peterson as it originally appeared in pharmaphorum and read the Goodroot weight loss drug guide it’s based on. Obesity rates in the United States have tripled since the 1980s. According to the CDC, a mind-boggling 41.9% of adults were obese as of 2020. Many …

Weighing the Pros and Cons, and Dollars and Cents, of the New Wave of Weight-Loss Drugs Read More »

Treating Hemophilia With Gene Therapy is a Powerful Option, But Patients Only Get One Chance

See this article by RemedyOne’s Jason Peterson as it originally appeared in Pharmaphorum.  Gene therapy has emerged as a novel approach in treating haemophilia. Rather than simply managing the disorder, this technique aims to correct an abnormality or malfunction in the patient’s body by using a vector to deliver corrected genetic material.  While not considered …

Treating Hemophilia With Gene Therapy is a Powerful Option, But Patients Only Get One Chance Read More »

Pharmacogenetics and Pharmacogenomics: The Future of Precision Medicine

Over the past five years, Sally struggled with depression, and despite trying various treatments, none seemed to benefit her. Recently, she visited a new psychiatrist who conducted a saliva swab for pharmacogenetic testing during her initial consultation. By combining Sally’s medication history and the pharmacogenetic test results, the psychiatrist discovered that several previously prescribed medications …

Pharmacogenetics and Pharmacogenomics: The Future of Precision Medicine Read More »

Hemophilia Gene Therapies: Are the World’s Most Expensive Drugs Really Worth It?

Hemgenix became the most expensive drug in the history of FDA-approvals back in November of 2022 after the manufacturer, CSL Behring, hung a $3.5 million dollar price tag on it. This was a first-of-its-kind therapy approved for the treatment of hemophilia, more specifically hemophilia B. Hemgenix is one of the newest agents utilizing gene therapy …

Hemophilia Gene Therapies: Are the World’s Most Expensive Drugs Really Worth It? Read More »

What Is a Cough Medicine Doing in My Anti-depressant?

This might come as a surprise to some individuals as they dive into the listed ingredients of the newest FDA-approved anti-depressant to hit the market, Auvelity. Let’s take a look at this new product and how a cough medicine found its way into this new treatment.  Auvelity is a combination product that contains dextromethorphan (yes, …

What Is a Cough Medicine Doing in My Anti-depressant? Read More »

Competition is on the Horizon for Costly Narcolepsy Treatments

See this article by RemedyOne clinical pharmacist, Jason Peterson, R.Ph. as it originally appeared in Pharmaphorum.  People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive daytime sleepiness and can be treated with a stimulant …

Competition is on the Horizon for Costly Narcolepsy Treatments Read More »

Mounjaro: Competing To Be the Best

Jason Peterson and RemedyOne EVP of clinical services Robert Louie have also written about Mounjaro for Pharmaphorum.  Man o’ War, Seabiscuit, Secretariat, Seattle Slew, Trulicity, Ozempic, Rybelsus, and Mounjaro. Racehorses and treatments for diabetes—all of which have a history of competing to be the best.    Just over 11% of the U.S. population currently has …

Mounjaro: Competing To Be the Best Read More »

Drug Treatment of Presbyopia: Medical Necessity or Convenience?

Some say things get better with age. Cheese, wine, and whiskey are a few examples that come to mind. Unfortunately, your vision is not one of them. As we enter our forties, most if not all of us will experience the natural loss of near vision, also known as presbyopia. Coined from the Greek terms …

Drug Treatment of Presbyopia: Medical Necessity or Convenience? Read More »

Drug Innovation Continues Despite a World-Wide Pandemic

While much of the world was on pause during the COVID-19 pandemic, there are definite signs that even a pandemic cannot hold back drug innovation. Despite the variety of challenges posed by the dreaded contagion, the FDA continued to churn out drug approvals in 2021 and innovate health advancements for the American public. Historically, December …

Drug Innovation Continues Despite a World-Wide Pandemic Read More »

High Cost, Lifelong Treatments and the Impact on Payers and Patients

Healthcare payers may not be familiar with the high costs of paroxysmal nocturnal hemoglobinuria (PNH), or even know what it is, that is until the ultra-expensive drugs prescribed to treat this condition start showing up on claim reports. With a yearly cost of treatment reaching nearly $1MM, payers and patients alike need to be considered …

High Cost, Lifelong Treatments and the Impact on Payers and Patients Read More »